Clinical trial
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
NCT00333502 · NewLink Genetics Corporation, Industry · Completed
Key facts
| NCT number | NCT00333502 |
|---|---|
| Title | Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors |
| Official title | A Phase 1b/2a Safety and Pharmacokinetic Study of CRLX101 (Formerly Named IT-101) in the Treatment of Advanced Solid Tumors |
| Lead sponsor | NewLink Genetics Corporation, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Cancer, Solid Tumor |
| Intervention type | Drug |
| Interventions | Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer |
| Enrollment | 62 |
| Start date | May 1, 2006 |
| Primary completion | Nov 1, 2011 |
| Completion | Apr 1, 2012 |
| First posted | Jun 5, 2006 |
| Last update posted | May 28, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: